Wedbush analyst Robert Driscoll lowered his price target for Corvus Pharmaceuticals to $11 from $19 as he pushes back potential approval of CPI-444 to be more conservative, as well as incorporate additional model tweaks. The analyst expects the company to present additional updates throughout 2019 for lead asset CPI-444 and CD73 inhibitor CPI-006, which are being evaluated in robust, broad monotherapy and combination studies in a variety of tumor types that he believes will provide clear insight into potential pivotal study designs. Driscoll is also encouraged by recent preclinical data for ITK inhibitor CPI-818 that is initiating a clinical study this quarter. The analyst reiterates an Outperform rating on the shares.